Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00059722 · ClinicalTrials.gov registry record · Phase 2
This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.
A Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT00059722: Completed Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Genzyme, a Sanofi Company.
NCT00059722 is a Phase 2 study of Carcinoma, Non-Small Cell Lung that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 160 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00059722, a Phase 2 study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy of ZD6474 and ZD1839 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ZD1839
- DRUG ZD6474
Study Locations (20)
California
- Research Site - Los Angeles
- Research Site - Palm Springs
- Research Site - San Diego
Florida
- Research Site - Boca Raton
- Research Site - Jacksonville
- Research Site - Orange Park
Missouri
- Research Site - Saint Loius
- Research Site - St Louis
New York
- Research Site - Brooklyn
- Research Site - New York
Other
- Research Site - Buenos Aires
- Research Site - Mendoza
Arkansas
- Research Site - Pine Bluff
Idaho
- Research Site - Coeur d'Alene
Illinois
- Research Site - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2003-05 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
What the finished NCT00059722 record still lists
NCT00059722 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00059722 names 20 study sites across 13 states, led by California, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT00059722 about?
NCT00059722 is a clinical study titled "This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.". The purpose of this study is to compare the efficacy of ZD6474 and ZD1839 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.
What is the current status of trial NCT00059722?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2003-05. Estimated completion is 2007-06.
What conditions does trial NCT00059722 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT00059722?
The interventions under investigation include: Placebo (DRUG), ZD1839 (DRUG), ZD6474 (DRUG).
Who is sponsoring clinical trial NCT00059722?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00059722 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00059722's enrollment target sits among peer trials
160 55th of 130 higher than 76 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
RECRUITING · Phase 2
-
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
RECRUITING · Phase 2
-
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
RECRUITING · Phase 2
-
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
RECRUITING · Phase 2
-
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia